AZ teams up with G1 on lung cancer combo
AstraZeneca has signed a deal with US group G1 Therapeutics to test the potential of a new combination therapy for lung cancer.
Read More
Tag: G1T38
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
